IP Verse

Method And Composition For Treating Ocular Hypertension And Glaucoma - EP2772249

The patent EP2772249 was granted to AGC on May 3, 2017. The application was originally filed on May 28, 2009 under application number EP14001862A. The patent is currently recorded with a legal status of "Revoked".

EP2772249

AGC
Application Number
EP14001862A
Filing Date
May 28, 2009
Status
Revoked
Jun 9, 2023
Grant Date
May 3, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEFeb 2, 2018-ADMISSIBLE

Patent Citations (28) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0850926
DESCRIPTIONEP0969846
DESCRIPTIONEP1011728
DESCRIPTIONEP1115406
DESCRIPTIONEP1321144
DESCRIPTIONEP1349580
DESCRIPTIONEP1547599
DESCRIPTIONEP1666043
DESCRIPTIONEP1825855
DESCRIPTIONEP1829545
DESCRIPTIONEP1905453
DESCRIPTIONEP1916002
DESCRIPTIONUS2007248697
DESCRIPTIONUS5409125
DESCRIPTIONUS5614172
DESCRIPTIONUS5807892
DESCRIPTIONUS5886035
DESCRIPTIONUS6096783
DESCRIPTIONUS6241124
DESCRIPTIONUS6344477
DESCRIPTIONWO2007042262
OPPOSITIONEP1321144
OPPOSITIONEP1825855
OPPOSITIONUS2005287325
OPPOSITIONWO0003736
SEARCHEP1321144
SEARCHEP1825855
SEARCHWO0003736

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Allergan Ltd, "GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container.", (20170406), pages 1 - 9, URL: https://www.medicines.org.uk/emc/product/1239/smpc/print, XP055461679
OPPOSITION- Anonymous, "DuoTrav", Drugs.com, (20180202), pages 1 - 2, URL: https://www.drugs.com/uk/duotrav.html#print, XP055461675
OPPOSITION- EGOROV, E. et al., "Adjunctive use of tafluprost with timolol provides additive effects for reduction in intraocular pressure in patients with glaucoma /Abstract/", Acta Ophthalmologica, (20070900), pages 1 - 2, XP055462093
OPPOSITION- E J Higginbotham, Diestelhorst M, Pfeiffer N, Rouland J F, Alm A, "The Efficacy and Safety of Unfixed and Fixed Combinations of Latanoprost and Other Antiglaucoma Medications", Surv Ophthalmol, (20020000), vol. 47, no. Suppl.1, pages S133 - S140, XP055461693
OPPOSITION- Merck & Co., Inc., "PRESERVATIVE-FREE STERILE OPHTHALMIC SOLUTION in a Sterile Ophthalmic Unit Dose Dispenser TIMOPTIC® 0.25% AND 0.5% (TIMOLOL MALEATE OPHTHALMIC SOLUTION) in OCUDOSE® (DISPENSER)", Data Sheet, (20050700), pages 1 - 7, XP055462098
OPPOSITION- Pfizer Limited, "Xalacom eye drops, solution", (20150716), pages 1 - 12, URL: https://www.medicines.org.uk/emc/medicine/7735/SPC/Xalacom+eye+drops,+solution/, XP055461686
OPPOSITION- SCHUMAN, J. S. et al., "Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension", American Journal of Ophthalmology,, (20050800), pages 242.e1 - 242.e11, XP027729492
OPPOSITION- BRASNU E et al., "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, (20080400), vol. 33, no. 4, pages 303 - 312, XP009108708
OPPOSITION- KUPPENS E V M et al., "Effect of timolol with and without preservative on the basal tear turnover in glaucoma", BRITISH JOURNAL OF OPHTHALMOLOGY, (19950400), vol. 79, pages 339 - 342, XP009108698
SEARCH- BRASNU E ET AL., "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, (200804), vol. 33, no. 4, pages 303 - 312, XP009108708 [Y] 1-15 * the whole document *
SEARCH- KUPPENS E V M ET AL., "Effect of timolol with and without preservative on the basal tear turnover in glaucoma", BRITISH JOURNAL OF OPHTHALMOLOGY, (1995), vol. 79, pages 339 - 342, XP009108698 [Y] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents